Clinical trials: Asthma Patients
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03215758
- Testing
- QAW039
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
The purpose of this study is to investigate the effectiveness of Alvesco® (Ciclesonide) compared with usual asthma care in the primary care setting.
- Trial name
- NCT00404547
- Testing
- Ciclesonide, Usual Care Inhaled Glucocorticosteroids
- Where
- 186 sites in Canada
- Volunteers
- 1,121 people
- Sponsor
- AstraZeneca
Asthma
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide [GB]) versus…
- Trial name
- TRIMARAN (NCT02676076)
- Testing
- CHF 5993 100/6/12.5, CHF 1535 100/6 µg
- Where
- Germany
- Volunteers
- 1,155 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
The primary objective of this trial is to evaluate the safety and efficacy of two doses of tiotropium inhalation solution delivered via the Respimat® inhaler once daily in the afternoon in patients (1 to 5 years old) with…
- Trial name
- NCT01634113
- Testing
- tiotropium-bromide
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 102 people
- Sponsor
- Boehringer Ingelheim
Asthma, Airway Obstruction
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
- Trial name
- NCT00736489
- Testing
- AZD3199, Formoterol
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Nasal Polyps
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years)…
- Trial name
- THUNDER (NCT03681093)
- Testing
- Fevipiprant 150 mg, Fevipiprant 450 mg
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of Different Doses of Indacaterol
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
- Trial name
- NCT01079130
- Testing
- Indacaterol, Salmeterol
- Where
- 71 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Medication Adherence, Medication Compliance
Connected Healthcare for Individuals Living at Home With Chronic Conditions
Managing and taking medications as prescribed can be a difficult task. This is especially true for older adults living at home with chronic conditions while managing multiple prescribed medications.
- Conditions
- Medication Adherence, Medication Compliance, Medication Nonadherence, Hypertension
- Trial name
- NCT04339296
- Testing
- Spencer
- Where
- Canada
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alberta Health Services, Calgary
Asthma
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch…
- Trial name
- QVM149 (NCT03108027)
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Asthma
Pediatric Ease of Use ELLIPTA Items
A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic subjects.
- Trial name
- NCT03315572
- Testing
- Interviewer administered version of ease of use items, Self-administered version of ease of use items, Caregiver version of ease of use items
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Childhood Asthma
Asthma Link: A Real World Application of School Supervised Asthma Therapy
The goal of this study is to assess the feasibility of a clinical trial to evaluate the impact and process of deploying school-supervised asthma therapy in a real-world setting for children with poorly controlled asthma (aged…
- Trial name
- NCT04942379
- Testing
- Asthma Link, Enhanced Usual Care
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Massachusetts, Worcester
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms
Overall Aim: To better understand the diagnostic process for prolonged respiratory events and determine the potential role of FeNO in assessing the possibility of asthma as the symptoms etiology.
- Trial name
- NCT01518322
- Testing
- NIOX MINO®
- Where
- 13 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Aerocrine AB
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-2 (NCT05281523)
- Testing
- Depemokimab (GSK3511294)
- Where
- 84 sites in United States, China and 7 more
- Volunteers
- 264 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
- Trial name
- ACE (NCT02230189)
- Testing
- Segmental airway allergen challenge, Bronchoscopy, Methacholine challenge test
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Prescott Woodruff
Asthma
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: To evaluate the safety and tolerability of dupilumab.
- Trial name
- NCT02414854
- Testing
- Dupilumab, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol
- Where
- 389 sites in United States, Argentina and 20 more
- Volunteers
- 1,902 people
- Sponsor
- Sanofi